Enhanced active metabolite generation and platelet inhibition with prasugrel compared to clopidogrel regardless of genotype in thienopyridine metabolic pathways
Dominick J Angiolillo(University of Florida), Oscar Ö. Braun(Lund University), Scott S. Sundseth, Kenneth J. Winters(Eli Lilly (United States)), Christoph Varenhorst, Neal S. Kleiman(Houston Methodist), Jorge F. Saucedo, Timothy M. Costigan(Eli Lilly (United States)), Joseph A. Jakubowski(Indiana Biosciences Research Institute), Suman Duvvuru(Eli Lilly (United States)), José Luis Ferreiro(Institut d'Investigació Biomédica de Bellvitge), Joseph R. Walker(Daiichi Sankyo (United States)), Mark B. Effron(Eli Lilly (United States))
Cited by 18
Related Papers
Prasugrel Compared With High Loading- and Maintenance-Dose Clopidogrel in Patients With Planned Percutaneous Coronary Intervention
|Circulation|2007|882
Pretreatment with Prasugrel in Non–ST-Segment Elevation Acute Coronary Syndromes
|New England Journal of Medicine|2013|651
A Randomized Trial of Prasugrel Versus Clopidogrel in Patients With High Platelet Reactivity on Clopidogrel After Elective Percutaneous Coronary Intervention With Implantation of Drug-Eluting Stents
|Journal of the American College of Cardiology|2012|617